A major challenge in developing an HIV-1 vaccine is to identify immunogens and their delivery methods that can elicit broad neutralizing antibodies against primary isolates of different genetic subtypes. Recently, we demonstrated that priming with DNA vaccines expressing primary HIV-1 envelope glycoprotein (Env) followed by recombinant Env protein boosting was successful in generating positive neutralizing antibody responses against a clade B primary HIV-1 isolate, JR-FL, that was not easily neutralized. In the current study, we examined whether the DNA priming plus recombinant protein boosting approach delivering a polyvalent primary Env formulation was able to generate neutralizing antibodies against primary HIV-1 viral isolates from various genetic subtypes. New Zealand White rabbits were first immunized with DNA vaccines expressing one, three or eight primary HIV-1 gp120 antigens delivered by a gene gun followed by recombinant gp120 protein boosting. Neutralizing antibody responses were examined by two independently executed neutralization assays: the first one was a single round infection neutralization assay against a panel of 10 primary HIV-1 isolates of subtypes A, B, C and E and the second one used the PhenoSense assay against a panel of 12 pseudovirues expressing primary HIV-1 Env antigens from subtypes A, B, C, D and E as well as 2 pseudoviruses expressing the Env antigens from MN and NL4-3 viruses. Rabbit sera immunized with the DNA priming plus protein boosting approach, but not DNA vaccine alone or Env protein alone, were capable of neutralizing 7 of 10 viruses in the first assay and 12 of 14 viruses in the second assay. More importantly, sera immunized with the polyvalent Env antigens were able to neutralize a significantly higher percentage of viruses than the sera immunized with the monovalent antigens. Our results suggest that DNA priming followed by recombinant Env protein boosting can be used to deliver polyvalent Envantigen-based HIV-1 vaccines to elicit neutralizing antibody responses against viruses with diverse genetic sequence variations.
Introduction
It remains a challenge to develop promising Human Immunodeficiency Virus Type 1 (HIV-1) vaccine candidates to be moved into phase III clinical trials. Lately, there has been notable progress in inducing protective immune responses based on cell-mediated immune (CMI) responses. By using the rhesus macaque model, several studies independently established protection of monkeys against the chimeric SHIV89.6 challenges (Amara et al., 2001; Barouch et al., 2000; Shiver et al., 2002) mainly based on the Gag-specific CMI responses. Virology 350 (2006) 34 -47 www.elsevier.com/locate/yviro While these studies clearly achieved protection by reducing the long-term viral setting point and avoiding the decline of CD4+ T-cell counts, none was able to induce a sterilizing immunity which demands an early and complete blocking of viral infection to the target cells-a task traditionally requiring the strong anti-viral neutralizing antibody responses (Mascola and Montefiori, 2003; Morris, 2002) . Despite the effort of the last two decades, there has been little progress toward the goal of generating broadly neutralizing antibody responses against HIV-1 through immunization. A frequently cited reason for this failure was that HIV-1 mutates all the time and the new escaping viral isolates prevent the development of vaccines based on only one HIV-1 envelope (Env) antigen (Wei et al., 2003) . There are two approaches to address this challenge. First, it was hoped that a common neutralizing antigen structure can be identified on most of the Env proteins from the primary HIV-1 isolates. A number of approaches have been put into this strategy in the last two decades, such as the principal neutralizing domain (PND) based on the V3 loop (Javaherian et al., 1989 (Javaherian et al., , 1990 , the broadly neutralizing monoclonal antibodies (Burton et al., 2005; Conley et al., 1994; Moulard et al., 2002; Muster et al., 1994; Purtscher et al., 1994; Scanlan et al., 2002; Zwick et al., 2001) , induction of fusion intermediates (LaCasse et al., 1999) and lately the consensus env gene sequences (Gao et al., 2004; Gaschen et al., 2002) . But so far none has led to the production of one single HIV-1 Env antigen which is capable of inducing broadly neutralizing antibody responses against multiple primary viral isolates. The other approach which has not been fully explored is the use of polyvalent antigens as vaccines (Hurwitz et al., 2005) . A nonhuman primate study showed that a polyvalent formulation consisting of HIV-1 Env antigens was able to induce stronger neutralizing antibodies and better protection against the chimeric SHIV viral challenge, but the protection was not correlated to the neutralizing antibody responses (Cho et al., 2001) . However, the above study only used Env antigen from clade B viral isolates. The polyvalent approach has not been well studied by using Env antigens from different clades of primary HIV-1 isolates circulating in the world.
One of the difficulties to develop polyvalent Env vaccines is the complex process to screen, select and produce multiple recombinant Env protein antigens. We have used DNA immunization as a tool in early stage preclinical studies to test polyvalent Env formulation. In this approach, multiple DNA vaccines expressing various primary Env antigens can be produced inexpensively and delivered easily in one mixture. The ability of DNA vaccines to elicit anti-Env antibody responses has been well documented with Env from T-cellline-adapted (TCLA) HIV-1 isolates (Lu et al., 1995 (Lu et al., , 1996 , and levels of anti-Env antibody responses can be further improved by using recombinant TCLA Env proteins as the boost (Barnett et al., 1997; Richmond et al., 1998) although recombinant Env proteins alone have not been very immunogenic in inducing strong antibody responses in both animal studies and human HIV vaccine trials (Ackers et al., 2003) . Recently, we used the DNA prime and protein boost approach in generating neutralizing antibody responses against JR-FL, a primary HIV-1 isolate relatively resistant to neutralization . The DNA prime and protein boost approach was also proven effective when a structurally modified JR-FL Env antigen (Beddows et al., 2005) or V2 domain deleted Env was used (Barnett et al., 2001) .
As a pilot study to test the feasibility of using the DNA prime and protein boost approach to deliver polyvalent Env vaccines, here we immunized New Zealand White (NZW) rabbits with DNA vaccines coding for primary Env antigens followed by recombinant Env protein boosts, either with single antigen or in various polyvalent combinations up to eight primary Env proteins. Data from the current study demonstrated that polyvalent gp120 DNA immunization was effective in generating antibody responses against a wide range of primary HIV-1 Env glycoproteins. Boosting these rabbits with the recombinant gp120 proteins further improved the titers and more importantly the neutralizing activities against primary viral isolates across several major subtypes circulating in the world. Based on data generated from this "proof-of-principle" pilot study, the polyvalent Env vaccine formulation delivered by the DNA prime and protein boost approach offers an attractive strategy to develop a clinical AIDS vaccine formulation to elicit neutralizing antibody responses with improved breadth.
Results
Selection and production of HIV-1 gp120 DNA and recombinant gp120 protein vaccines
In the current study, eight primary HIV-1 envelope glycoproteins were randomly selected from 7 different subtypes (clades A to G) of HIV-1 M group. As shown in Fig. 1 , this group of primary viral samples was collected from HIV-1- Fig. 1 . Design of animal groups for DNA prime and protein boost immunization study. New Zealand White rabbits received either DNA vaccines (monovalent or polyvalent components) or plasmid vector control at weeks 0, 4, 8 and 16 followed by two boosts with recombinant gp120 glycoproteins at weeks 40 and 44. The gp120 form of Env antigens was used for both DNA prime and protein boost. The original sources of viral isolates from which the primary gp120 genes were cloned are listed at the bottom of the figure. infected patients in Africa, North America, Asia and South America which include both R5 and X4 phenotypes (Gao et al., 1996) . The gp120 gene inserts were PCR amplified from the full-length env genes with the high fidelity PFU polymerase and subcloned into the DNA vaccine vector pSW3891, a vector for potential human clinical trial use derived from the pJW4303 vector as previously reported . The ability of DNA vaccines to express gp120 antigens was confirmed in transiently transfected 293T cells before being used in animal study. Four of these primary env genes were further expressed as recombinant gp120 glycoproteins in stably transfected 293 cells, and the purified gp120 proteins were used for the boost.
Immunization schedule of DNA plus protein formulation
The immunogenicity of primary HIV gp120 DNA vaccines was studied as either monovalent, 3-valent or 8-valent combinations in NZW rabbits (Fig. 1 ). In the DNA priming phase, each animal received four DNA immunizations by a gene gun at weeks 0, 4, 8 and 16. The total amount of DNA at each immunization was fixed at 36 μg, but the dose for each gp120 DNA vaccine varies depending on the number of DNA vaccines included in the polyvalent formulations. In the 3-valent group, the dose for each DNA plasmid was 12 μg, while in the 8-valent group, the dose was 4.5 μg each (Fig. 1) . The protein-boosting phase consisted of two intradermal immunizations of recombinant gp120 mixed with Incomplete Freund Adjuvant (IFA) at weeks 40 and 44. For the monovalent and 3-valent DNA groups, the homologous gp120 recombinant proteins were used as the boost. For the 8-valent DNA group, the protein boost consisted of 4-valent recombinant gp120 proteins (Fig. 1 ), which were homologous to 4 of 8 DNA vaccine components used during priming phase. The dose of protein boost at each immunization was fixed at a total amount of 100 μg per immunization. The control group received 4 times of empty pSW3891 DNA vector inoculations followed by twice 4-valent recombinant gp120 protein boosts as described above.
Anti-gp120 IgG responses in rabbit sera after DNA priming At the end of DNA priming, substantial levels of antibody responses were induced in both monovalent and polyvalent gp120 DNA vaccine groups against the primary HIV-1 gp120 antigens as measured by ELISA. The overall immunogenicity of 4 individual gp120 DNA vaccines (B, Bal, C and E) was very similar. The anti-gp120 IgG titers reached ∼1:100,000 even though the rabbit sera usually recognized the homologous gp120 antigen slightly better (indicated by an arrow in Fig. 2A ) Fig. 2 . HIV-1 gp120-specific IgG responses at the end of DNA priming. (A and B) Levels of anti-gp120 IgG were measured by ELISA for rabbits sera immunized with either the monovalent DNA vaccines expressing one of the four primary gp120 antigens (A) or the polyvalent DNA vaccines expressing 3 or 8 primary gp120 antigens (B). The DNA vaccines used are marked at the right upper corner of each panel. The arrows indicate where the homologous gp120 were used as the coating antigens. Geometric means of the anti-gp120 IgG titers against each particular gp120 antigen are shown with standard deviations. The mean serum titers from polyvalent rabbits were marked by the horizontal lines. The difference between 3-valent and 8-valent was statistically significant based on the Student's t test (p < 0.02). (C) Specificity of rabbit anti-gp120 IgG analyzed by the Western blot. Equal amounts of secreted gp120 antigens (10 ng) from transiently transfected 293T cells were loaded onto each lane of SDS-PAGE. Rabbit sera collected 2 weeks after the fourth DNA immunization were used at a dilution of 1:500.
than the other primary gp120 antigens, except the DNA vaccine expressing C gp120 antigen. For rabbits which received 3-valent DNA vaccines, the preferred recognition for homologous gp120 antigen disappeared. Similarly, the rabbit sera from the 8-valent DNA vaccine group also had comparable reactivity against most of the eight primary gp120 antigens. It was interesting to observe that the mean titer of 3-valent DNA vaccine group was higher than that from the 8-valent DNA Fig. 3 . Improvement of anti-gp120 IgG responses after protein boosts in rabbits primed with various DNA vaccine formulations as analyzed by ELISA. Rabbit sera were collected prior to the DNA immunizations (Pre-bleed), 2 weeks after the fourth DNA immunization (DNA-prime), 2 weeks after the first (Protein-I) and the second (Protein-II) protein boost immunizations. Four recombinant gp120 proteins (B, C, E and Bal) were used, either alone or in combinations, for the boost (see design in Fig. 1 ). (A) Sera from rabbits immunized with the monovalent DNA plus protein gp120 vaccines. (B) Sera from rabbits immunized with the polyvalent DNA plus protein gp120 vaccines. (C) Sera from rabbits received empty vector DNA followed by protein boosts (as shown in Fig. 1 ). Table 1 Neutralization activities against HIV-1 primary isolates from clades A, B, C and E Rabbit sera used at 1:5 dilution were collected at 2 weeks after the fourth DNA immunization (Post-DNA), 2 weeks after the first protein boost (Protein-I) and 2 weeks after the second protein boost (Protein-II). Virus neutralization assays were performed using a single round of infection with flow cytometry measurement of intracellular HIV-1 p24-Ag in HIV-1-infected T cells. The percent neutralization of each rabbit serum was calculated by the reduction in the number of p24-Ag positive cells in the test wells with immune sera, compared to the number of p24-Ag positive cells in wells containing pre-immune sera. To quantify the p24 positive PBMC, background events in mock-infected cells were subtracted. Each immune rabbit serum was compared to their pre-immune sera. "-" indicates that vaccine group (p < 0.02) (Fig. 2B ) although the frequency of immunizations and the total amount of DNA vaccines at each immunization were the same for both groups. The higher titer of gp120-specific antibody in 3-valent immunized rabbit sera was further confirmed by Western blot analysis that the 3-valent sera had stronger and broader reactivity against primary gp120 antigens than the 8-valent sera (Fig. 2C) .
Anti-gp120 IgG responses after protein boost DNA immunized rabbits were further boosted with two protein immunizations. For the monovalent group, there was a quick elevation of anti-gp120 IgG responses after only one protein boost as measured by ELISA (Fig. 3A) . The anti-gp120 titers did not improve significantly with the second protein boost, suggesting that one protein immunization was sufficient to boost the anti-gp120 antibody titer to the peak levels in these animals. Similarly, for 3-valent group, one protein immunization boosted the anti-gp120 IgG response close to their peak levels against each of the three primary gp120 antigens included in the DNA prime and protein boost. The effects of the second protein boost were minimal (Fig. 3B) .
Anti-gp120 antibody responses in rabbits immunized with the 8-valent DNA formulation showed a very different pattern and increased with each of the two protein boosts (Fig. 3B ). One protein boost was effective in improving the anti-gp120 IgG titers, but the levels were clearly lower than that achieved after the second protein boost. Because the anti-Env IgG titers at the end of DNA priming were already lower in the 8-valent DNA group than that in the 3-valent DNA group (Fig. 2B) , the above data would suggest that one protein boost was not sufficient for the 8-valent DNA group to achieve the antibody responses to the same plateau level as the 3-valent DNA group after one protein boost. Protein boosts alone in control animals without gp120 DNA vaccine priming were unable to elicit high level of anti-gp120 IgG responses (Fig. 2C ).
Neutralization against primary HIV-1 viral isolates using a single round infection assay system Neutralization activities of the above rabbit sera elicited by the DNA prime and protein boost approach were analyzed independently by two different neutralization assays. The first one was conducted against a panel of 10 primary HIV-1 isolates (Table 1) , using a flow-cytometry-based single-round infection system to detect HIV-1-infected T cells by intracellular staining for HIV-1 p24 . This assay directly compares pre-immune and post-immune rabbit sera, a value of 50% neutralization or above is clearly positive and reproducible . At the end of DNA priming, no significant neutralizing activity was detected except that against HIV-1 isolate SF162, a virus that is sensitive to neutralization. After only one protein boost, however, we detected positive neutralizing activities against multiple primary viruses, including SF162, Bal, JRCSF (clade B), TV1 (clade C) and DJ263 (clade A). After the second protein boost, more sera showed positive neutralizing activities, including those that attained higher strength (>75%, shown in orange shaded areas) and those against additional primary isolates such as S007 and DU151 (clade C) ( Table 1 ). The negative control rabbit sera Table 2 Neutralizing antibody titers against HIV-1 pseudoviruses in immunized rabbit sera a Animal Groups N16  3975 7730 2042  150  143  421  111  183  74  65  69  95  80  124  Pre- 
Control antibodies
indicates that the neutralizing activities were below 50% inhibition at 1:15 serum dilution. a Sera at the peak level anti-gp120 antibody responses (2 weeks after the second protein boost) were used in this assay. The starting serum dilution was 1:15.
(G01 and G02), which received the empty DNA vector as prime, showed no significant neutralizing activities even after two gp120 protein boosts. We used two broadly neutralizing monoclonal antibodies (mAb), 2F5 and 2G12, and the pooled human immunoglobulin from HIV-infected patients (HIVIG) as positive controls. Although 2F5 and 2G12 demonstrated consistent neutralizing activities at 50 μg/ml, they could not neutralize several primary viral isolates, producing a pattern very similar to that of rabbit sera elicited by our DNA prime plus protein boost approach (Table 1) . Whereas 2F5 had positive neutralizing activities against two clade E viral isolates, 2G12 had weaker and narrower neutralizing activities than several rabbit sera. At a reduced concentration (5 μg/ml), both mAbs showed much weaker neutralizing activities. As learned from recent report, these two mAbs may not be effective against clade C viruses (Binley et al., 2004) .
HIVIG at 10 mg/ml had broad and strong neutralizing activities, but at 1 mg/ml, its activities reduced to a level similar to that of rabbit sera induced by the DNA prime plus protein boost immunization approach (Table 1 ). The total normal human blood IgG level is 8 to 15 mg/ml, so purified HIVIG, at 10 mg/ml of IgG, equals undiluted human sera. The range of total IgG in our rabbit immune sera was 15-25 mg/ml, and the average of gp120-specific IgG was at 200 μg/ml after two protein boosts. At 1:5 sera dilution, total IgG in rabbit sera would be at 3-5 mg/ml and gp120-specific IgG at 40 μg/ml.
Neutralization against primary HIV-1 viral isolates using a pseudotyped virus system
The second neutralization assay was conducted by using a PhenoSense assay system (Richman et al., 2003) against a panel of 12 pseudotyped viruses expressing primary HIV-1 Env antigens. Two T-cell-line-adapted (TCLA) HIV-1 viruses (MN and NL4-3) were also included. In this assay, the levels of neutralizing activities in rabbit immune sera were quantitatively determined by the end titration titers that were able to generate >50% neutralization.
Based on the results learned from the first neutralization assay, we only included the rabbit sera after the second protein boost for this pseudovirus-based assay. Rabbit sera immunized with DNA prime and protein boost approach had overall high levels of neutralizing antibody responses (Table 2) . Their titers against MN and SF162 were even better than the positive control HIV patient sera N16 that was used in a recent report with proven high level neutralizing antibody activities against a wide range of primary HIV-1 isolates (Binley et al., 2004) . The DNA prime plus protein boost approach also elicited various levels of neutralizing antibodies against NL4-3 and 9 other viruses which express primary HIV-1 Env antigens from clade A (92RW020 and 94UG103), clade B (92BR020 and 92US715), clade C (93IN905 and 98CN006), clade D (94UG114) and clade E (92TH021 and CMU02). These viruses were more resistant to neutralization since the positive control sera N16 showed much lower neutralizing antibody titers than that against SF162 ( Table 2 ). The neutralizing antibody titers in rabbit immune sera were comparable or close to that of N16 against the clades A, B and C primary Env antigens, but lower than N16 against clades D and E primary Env antigens. Two viruses, one from clade B (JRCSF) and one from clade D (92UG046), were not neutralized by any of the rabbit immune sera. The control rabbit sera which received protein alone immunizations had only meaningful neutralizing antibodies against MN and SF162 but occasional neutralizing activities against 2 other primary viruses (Table 2) .
Further analysis on the breadth of neutralizing activities revealed clear advantage of the polyvalent Env formulations (Fig. 4) . The frequencies of positive neutralization by monovalent or polyvalent formulations were calculated as the percent of positive neutralization events as part of the total neutralization events against either clade B, non-clade B or all 14 HIV-1 pseudoviruses. The frequencies of positive neutralization against these HIV-1 pseudoviruses were significantly different between the monovalent and polyvalent groups. The frequency for polyvalent sera to neutralize all 14 viruses included in the assay was 67.86%, while the frequency for monovalent sera was 38.39% (p < 0.001). When clade B and non-clade B viruses were analyzed separately, the polyvalent sera have a neutralization frequency of 56.25% against the 8 viruses from clades A, C, D and E as compared to the monovalent group that only had a frequency of 14.06% against the same set of non-clade B viruses (p < 0.001). Protein immunizations alone sera were clearly less capable in generating broad neutralizing antibody responses (Fig. 4) . The overall titers against non-clade B viruses were lower than that against clade B viruses as indicated at the bottom of Fig. 4 .
Discussion
The important role of the neutralizing antibody in HIV vaccine development has been supported by many studies including the protection of non-human primates with passive transfer of neutralizing monoclonal antibodies (Mascola, 2002; Mascola et al., 1999 Mascola et al., , 2000 Nishimura et al., 2002 Nishimura et al., , 2003 Ruprecht et al., 2001 Ruprecht et al., , 2003 Shibata et al., 1999; Xu et al., 2002) . Broadly neutralizing antibodies have been demonstrated in some of the HIV-infected patients (Bures et al., 2002; Pilgrim et al., 1997) , but the production of such antibody in infected patients seems always one step behind their escape mutants (Wei et al., 2003) . However, for a prophylactic HIV vaccine, it is still a desired scenario to induce broad neutralizing antibodies in a high-risk population before being infected with HIV because such broad humoral immunity is important to prevent the invading virus from establishing a persistent infection.
There are a number of obstacles to the development of HIV-1 vaccines that are capable of inducing broad neutralizing antibody responses. The first is the poor immunogenicity of Env proteins. Recombinant HIV-1 envelope protein-based HIV vaccines were unable to elicit high level antibody responses in a number of early human clinical studies (Belshe et al., 1993; Keefer et al., 1994 ; Salmon-Ceron et al., 1995; Valentine et al., 1996) . In recently published phase III HIV vaccine trial reports, the antibody responses remained suboptimal, although volunteers had received 7 immunizations of recombinant gp120 proteins (Gilbert et al., 2005a (Gilbert et al., , 2005b . The mechanism for such a poor immunogenicity is not well studied, but it was hypothesized that the heavy glycosylation and complicated oligomer structure may have contributed to such phenomenon (Moore and Burton, 2004) .
The second major obstacle is the high mutation rate in HIV which makes it difficult for any candidate HIV vaccines targeting at only one particular Env antigen. Previous attempts to develop vaccine candidates based on fusion intermediates (LaCasse et al., 1999) or specific epitopes modeled after the monoclonal antibodies Liang et al., 1999; McGaughey et al., 2003; Zwick et al., 2003) have not had much success. The more recent strategies of using consensus or ancestor sequences based on computer analysis of HIV gene sequences have not shown broadly neutralizing antibodies, even though the cross reactivity of immune sera against selected HIV envelope antigens may have been improved (Gaschen et al., 2002) .
The current pilot study is part of our continued effort to address these two major obstacles with a different approach. Over the last decade, the DNA immunization technology has been widely accepted as a tool to induce cell-mediated immune responses. However, our previous studies have also suggested that DNA immunization is equally powerful in inducing high level antibody responses against HIV antigens in both small animal and non-human primate models including neutralizing antibodies against primary SIV virus (Lu et al., 1995 (Lu et al., , 1996 . DNA immunization offers a unique advantage to further modify the envelope antigens to make them more immunogenic (Barnett et al., 2001; Lu et al., 1998) . More importantly, it was shown that the levels of neutralizing antibodies are improved when recombinant HIV envelope proteins are given as a boost to animals already primed with the DNA vaccines expressing the HIV envelope antigens . Such DNA prime plus protein boost approach was also effective in a non-human primate study (Letvin et al., 1997) , although mainly the HIV-1 TCLA viral isolate antigens were used in the above studies. Recently, we demonstrated that the DNA prime plus protein boost approach was effective in eliciting neutralizing antibody response against JR-FL, a viral isolate relatively difficult to be neutralized ).
In the current study, we further tested whether multiple primary HIV envelope antigens can be administered with the DNA prime plus recombinant protein boost approach. Our data confirmed that polyvalent DNA formulation alone was already effective in inducing strong binding antibody responses against a wide range of primary Env antigens, although such immune sera were not able to neutralize most of the primary HIV-1 viruses. With only one protein boost, positive neutralizing activities against primary HIV viral isolates were clearly detected. A second protein boost was able to increase both the titer and breadth of neutralizing antibody responses against a wide range of primary isolates from different clades. Thus, our data provided important evidence that the DNA prime plus protein boost vaccine strategy is effective in delivering polyvalent, primary Env-based HIV vaccine formulations to elicit neutralizing activities with improved breadth.
It was also interesting to observe that both monovalent and 3-valent DNA vaccine formulations were more immunogenic than the 8-valent formulation at the priming phase. Such difference also affected the numbers of protein boosts required to reach the peak level antibody response. It is possible that the 8-valent DNA group with reduced dose for each DNA vaccine component may have led to the reduced antibody responses due to the dilution effect to the immunogens. However, even sera from the monovalent and 3-valent groups could at least partially recognize heterologous primary gp120 antigens. Therefore, the exact mechanism may be more complicated. It may also suggest the existence of limitation on clonal expansion of memory B cell populations. When a large numbers of antigens with similar structures are delivered, there may be a competition in the simultaneous expansion of these clones so the total antibody responses may be lower than when less numbers of antigens are delivered at the same time. Further studies on the above mechanisms are needed because they will guide the ultimate decision on what will be the optimal numbers of Env antigens to be incorporated in a polyvalent Env vaccine formulation.
We noticed that, for the monovalent and 3-valent formulations, the breadth of neutralizing activities increased further after the second protein boost, but the ELISA titers did not (Table 1 and Fig. 3 ). The exact mechanism of this phenomenon is not clear. It is possible that the second protein boost might further improve the antibody responses against carbohydrate or other conformational epitopes primed by DNA vaccines, which were not reflected in the ELISA-based binding antibody assay. It is also possible that the second protein boost might lead to better antibody maturation with increased antibody avidity as we recently reported which may further improve the quality of neutralizing activity.
Our data also demonstrated similar utility for two different types of neutralization assays. Overall, the flow-based neutralization was more stringent to give high titers and thus a high percentage inhibition (>75%) would represent meaningful neutralizing activities even at low sera dilutions (Mascola et al., 2005) . A unique finding was that HIV-1 isolate JFCSF was neutralized in flow-based assay but not neutralized in the pseudotyped virus assay (Tables 1 and 2 ). There are several possibilities. First, the target cells used in these two assays were different. Second, the serum dilution may also be partially responsible (1:5 in flow-based assay and 1:15 in pseudotyped virus assay).
The polyvalent formulations included in this pilot study were selected purely based on the available primary Env antigens at the time when we started this study several years ago. While they represented different genetic clades, early studies demonstrated that the neutralizing antibody responses did not follow the genetic sequences of primary antigens , but recent studies also suggested a weak correlation between serum neutralization and the genetic clade (Binley et al., 2004) . Our finding that polyvalent formulations were more effective in generating broader neutralizing antibody responses than monovalent Env formulations will open a door for more such studies. For example, we need to know whether certain primary Env antigens will be more effective than others in inducing broad neutralizing antibody responses. Such Env antigens will be better candidates for polyvalent Env formulations than randomly selected Env antigens. Based on the results of these studies, additional polyvalent formulations with completely different set of primary Env antigens will be tested to see whether the breadth of neutralizing antibodies shown in the current study can be further improved because in current study there were still viruses that were completely resistant to the rabbit immune sera.
In addition, the ability of DNA prime and protein boost approach to elicit neutralizing antibodies through immunization will allow further studies to map the critical neutralizing epitopes which was not included in the current pilot study. For polyvalent Env formulations, it is even more important to know whether the breadth of neutralizing antibodies is dependent on more positive neutralizing epitopes or against several versions of the major epitopes, e.g. the V3 epitope of Env proteins from different genetic clades.
We also need to expand the size of animal groups to determine whether the 3-valent and 8-valent formulations are equally effective in eliciting the same breadth of neutralizing antibody responses. The most important questions, of course, would be whether the same DNA prime plus protein boost approach can generate broad neutralizing antibody responses in human studies. Nevertheless, results presented in this pilot study provided a technical platform to allow us to develop more effective HIV vaccines by using polyvalent Env formulations.
Materials and methods

DNA vaccines
The HIV env gene clones coding for A-120, B-120, C-120, D-120, E-120, F-120 and G-120 were received from Drs. Feng Gao and Betrice Hahn, University of Alabama at Birmingham. The gene coding for Bal-120 was prepared under contract with the National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with the Institute of Human Virology. The DNA vaccine inserts coding for the above eight primary gp120 antigens were first PCR amplified by using PFU polymerase (Stratagene, La Jolla, CA) and subcloned into the DNA vaccine vector pSW3891. A pair of consensus PCR primers were designed and used to amplify eight different gp120 genes: the plus strand primer GP120-p-f1 (p-cttgtgggtcacagtctattatggggtacc) and the minus strand primer GP120-p-b1 (ggtcggatccttactccaccactcttctctttgcc). The pSW3891 was derived from pJW4303 with the following modifications: the SV40 origin sequence was deleted and the Ampicillin resistance gene was replaced by the Kanamycin resistance gene. The pSW3891 contains the CMV immediate early (IE) promoter and its associated Intron A sequence. The HIV-1 gp120 inserts were fused in frame with a tissue plasminogen activator (tPA) leader sequence. The gp120 DNA vaccine plasmids grown in E. coli (HB101 strain) were prepared by using the Giga-plasmid purification kit (Qiagen, Valencia, CA) after their expressions were first confirmed by Western blot analysis using transiently expressed gp120 from 293T cells.
Protein vaccines
The recombinant gp120 proteins (B, Bal, C and E) were expressed in stably transfected 293 cells under the control of CMV promoter. The gp120 genes were cloned in frame with the tPA signal peptide to achieve secretion of the protein into the medium. The gp120 expression vector also contains neomycin phosphotransferase (neo) gene for the selection of stable HIV-1 gp120 expressing 293 cells in the presence of the drug Geneticin (G418 sulfate). Cell lines stably transfected with gp120 env genes were adapted to grow in serum-free medium. Secreted gp120 protein from the conditioned medium was purified by either Galanthus nivalis lectin or immunoaffinity chromatography with an anti-gp120 monoclonal antibody directed towards a conformational epitope on the glycoprotein (unpublished results).
Immunization
Female New Zealand White (NZW) rabbits of 6-8 weeks old (∼2 kg of body weight) were purchased from Millbrook Farm (Amherst, MA) and housed in the animal facility managed by the Department of Animal Medicine at the University of Massachusetts Medical School in accordance with IACUC approved protocol. Groups of rabbits first received four DNA immunizations at weeks 0, 4, 8 and 16 by a Bio-Rad Helios gene gun (Bio-Rad, Hercules, CA). The gp120 DNA vaccine plasmids or the negative control pSW3891 vector plasmid were coated on to the 1.0 μm gold beads at a ratio of 2 μg of DNA per mg of gold. Each gene gun shot delivered 1 μg of DNA and a total of 36 non-overlapping shots were delivered to each rabbit on shaved abdominal skin at each immunization. The animals then received two monthly recombinant gp120 protein boosts at weeks 40 and 44. A total of 100 μg recombinant gp120 proteins was administered intradermally with Incomplete Freund's Adjuvant (IFA, Sigma, St. Louis, MO) at each protein immunization. The serum samples were collected immediately before and 2 weeks after each immunization.
In vitro expression of gp120 antigens by DNA vaccines
The expression of primary gp120 antigens from DNA vaccine plasmids was conducted in transiently transfected 293T cells (Numa et al., 1995; Pear et al., 1993) . The 293T cells were grown in Dulbecco's Modified Eagle Media (DMEM, Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 μg/ml of streptomycin and 100 IU/ml penicillin. Each of the 60-mm tissue culture dishes (2.5 × 10 6 cells) was transfected with 10 μg of individual gp120 DNA vaccine plasmid or the empty pSW3891 vector by calcium phosphate precipitation (Batard et al., 2001 ). The supernatants were harvested 72 h post-transfection, and the gp120 proteins were then used for ELISA or Western blot analysis. The concentration of each gp120 antigen was determined by a quantitative ELISA using the recombinant gp120 protein with known concentration as the standard.
Enzyme-linked immunosorbent assay (ELISA)
Rabbit sera were tested for gp120-specific IgG antibody responses by ELISA. 96-well microtiter plates (Corning, NY) were first incubated with ConA (5 μg per well in 100 μl of PBS, pH 7.2) for 1 h then coated with 100 μl of gp120 antigens (1 μg/ ml) from transiently transfected 293T cell supernatant. After wells were blocked with 200 μl/well of blocking buffer (4% milk-whey in PBS) for 1 h, 100 μl of serially diluted rabbit sera was added in duplicate wells and incubated for 1 h. Following the antibody incubation, 100 μl of biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA) at 1:1000 dilution was added to each well and incubated for 1 h, horseradishperoxidase (HRP)-conjugated streptavidin (Vector Laboratories) at 1:2000 dilution was then added (100 μl/well) and incubated for 1 h. Between each step, the plates were washed 5 times with washing buffer (PBS at pH 7.2 with 0.1% Triton X-100). Finally, 100 μl/well of fresh TMB substrate (Sigma) was added and incubated for 3.5 min. The reaction was stopped by adding 50 μl of 2 N H 2 SO 4 . The absorptance was measured at the optical density (OD) of 450 nm (OD 450 ). The end titration titer was determined when the OD 450 value at the greatest serum dilution was 2-fold higher than the OD 450 value of the negative control wells with the normal rabbit sera. The difference between certain sets of anti-gp120 IgG titers was further analyzed for statistical significance by the Student's t test.
Western blot analysis
The gp120 antigens (10 ng/lane) in supernatants from transiently transfected 293T cells were subjected to SDS-PAGE and blotted onto PVDF membrane. Blocking was done with 0.1% I-Block (Tropix, Bedford, MA). The membranes were incubated with immunized rabbit sera at 1:500 dilution for 45 min and subsequently reacted with AP-conjugated goat antirabbit IgG at 1:5000 dilution for 30 min. Membranes were washed with blocking buffer after each step. Western-light substrate was then applied to the membranes for 5 min. Once the membranes were dried, X-ray films were exposed to the membrane and developed by a Kodak processor.
Neutralization assays
The first virus neutralization assay was performed using a single round of infection flow cytometric assay, as previously described . This assay detects HIV-1-infected T cells by intracellular staining for HIV-1 p24-Ag. A protease inhibitor is used to prevent secondary rounds of virus replication . Briefly, 40 μl/well of HIV-1 virus stock (multiplicity of infection ∼0.1) was incubated with 10 μl of heat inactivated rabbit serum, or control antibody, for 30 min at 37°C. The serum dilution and antibody concentration were defined at this step. After the incubation, 20 μl of mitogen stimulated CD4+ T cells (1.5 × 10 5 cells) was added to each well. Cells were maintained in IL-2 culture medium containing 1 μM indinavir, and the cells were fed on day 1 with 150 μl of IL-2 culture medium containing indinavir. T cells were harvested for intracellular p24-Ag staining on day 2. The cells were transferred to V-bottom plates and washed once with phosphate-buffered saline (PBS) containing 1% FBS. Then, cells were fixed and permeabilized using the Cytofix/Cytoperm Kit (BD-PharMingen, San Diego, CA) followed by two washes using the washing buffer provided by the manufacturer. The permeabilized cells were stained for 20 min at 4°C with 50 μl of a phtcoerythrin (PE)-conjugated mouse anti-p24 mAb (KC57-RD1, Beckman Coulter, Inc., Fullerton, CA). After two additional washes, the HIV-1-or mock-infected cells were analyzed with a FACS Calibur flow cytometer (Becton Dickinson, Franklin Lake, NJ) and the data analysis was performed with FlowJo software (Tree Star Inc., Ashland, OR). Live cells initially gated by forward and side scatter were analyzed for p24 positive cells. After forward and side scatter gating, 50,000 events were counted. Final quantitation of p24 positive PBMC was done by subtraction of background events in mock-infected cells. For each rabbit serum, the percent neutralization was derived by calculating the reduction in the number of p24-Ag positive cells in the test wells with immune sera, compared to the number of p24-Ag positive cells in wells containing pre-immune sera. In each case, the immune rabbit sera were compared directly to the pre-immune sera from the corresponding animal. All assays included additional control wells with a commercial pooled normal rabbit sera (Gemini Bio-Products, Woodland, CA), as well as positive control wells containing well-characterized monoclonal or polyclonal neutralizing antibodies (described below). Standard operating procedures prescribed the acceptable positive and negative control values, and all data shown are from assays that met these criteria. Using this assay format that directly compares preimmune and post-immune rabbit sera (here done at a serum dilution of 1:5), we consider values of 50% neutralization to be clearly positive and reproducible.
The second neutralization assay (PhenoSense Assay) used recombinant viruses pseudotyped with virus envelope proteins being tested. Pseudovirus were harvested 48 h after cotransfecting HEK293 cells with pCXAS-env libraries plus an HIV genomic vector that contains a firefly luciferase indicator gene (Richman et al., 2003) . Then, they were incubated for 1 h at 37°C with serial 4-fold dilutions of heat-inactivated rabbit sera. U87 cells that express CD4 plus the CCR5 and CXCR4 coreceptors were inoculated with virus dilutions in the absence of added cations. Virus infectivity was determined 72 h postinoculation by measuring the amount of luciferase activity expressed in infected cells. Neutralizing activity is calculated as the percent inhibition of viral replication (luciferase activity) at each antibody dilution compared with an antibody-negative control: % inhibition = {1 − [luciferase + Ab/luciferase − Ab]} × 100. Titers were presented as the reciprocal of the plasma dilution conferring 50% inhibition (IC 50 ) (Richman et al., 2003) . Statistical analysis with Chi-square test method was used to analyze the differences between different groups of rabbit sera.
HIV-1 viruses
HIV-1 primary isolates, and the T-cell-line-adapted HIV-MN Zolla-Pazner et al., 1998) , were obtained from NIH AIDS Research and Reference Reagent Program. HIV-1 strains ADA, SF162, Bal and JRCSF are clade B and well-characterized macrophage-tropic viruses using CCR5 as coreceptor (Baba et al., 2000; Dragic et al., 1998; Stauber et al., 1999; Zhang et al., 1999) . DU151 and S007 are clade C viruses that have been previously described (Bures et al., 2002) . TV1 (clade C) was provided by David Montefiori (Duke University) and Estrelita Janse Van Rensburg (University of Stellenbosch, South Africa). CM235 and CM244 are clade E viruses, which are macrophage-tropic and use CCR5 coreceptor (Baba et al., 2000; Baik et al., 1999; Subbarao et al., 2000) . DJ263 is a clade A virus. CM235, CM244 and DJ263 were provided by investigators from the U.S. Military HIV Research Program. All primary viral stocks were prepared and titrated in PHA and IL-2 stimulated human peripheral blood mononuclear cells (PBMC).
Other viruses used in PhenoSense Assay were pseudovirus developed to measure antiretroviral drug resistance during a single round of virus replication and adapted to measure virusantibody neutralization (Petropoulos et al., 2000) . HIV genomic RNA was isolated from virus stocks or plasma, and Env PCR products were cloned into the pCXAS expression vector and transformed into competent E. coli (Invitrogen). Pseudovirus particles were produced by cotransfecting HEK293 cells with pCXAS-env libraries plus an HIV genomic vector that contains a firefly luciferase indicator gene (Richman et al., 2003) . The list of pseudovirus used in the assay was: clade A (92RW020 and 94UG103), clade B (92BR020, 92US715, MN, SF162, NL4-3 and JRCSF), clade C (93IN905 and 98CN006), clade D (92UG046 and 94UG114) and clade E (92TH021 and CMU02).
HIVIG and monoclonal antibodies (mAbs)
Anti-HIV-1 human mAb 2G12 recognizes a carbohydratedependent, conformationally sensitive region of gp120 outside the CD4 binding site . Human mAb 2F5 binds to a linear epitope in the extracellular region of gp41 (Conley et al., 1994; Purtscher et al., 1996) . Both mAbs were kindly provided by Hermann Katinger (Vienna, Austria). HIVIG is purified IgG from pooled HIV-1 seropositive plasma which was collected from multiple donors (Lambert et al., 1997 
